Evidence map›Paper›PMID 40130247›Full record

ArticleFrontiers in medicine2025

Shumin Chen, Lu Gao, Lin Feng, Zheng Wang, Ye Li, Qing Liu, Wenjie Song, Shu Kong, Yang Liu, Jin Lu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shumin ChenBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation for Hematological Diseases, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Lu GaoBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation for Hematological Diseases, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Lin FengBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation for Hematological Diseases, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Zheng WangBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation for Hematological Diseases, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Ye LiBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation for Hematological Diseases, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Qing LiuBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation for Hematological Diseases, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Wenjie SongBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation for Hematological Diseases, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Shu KongBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation for Hematological Diseases, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Yang LiuBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation for Hematological Diseases, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Jin LuBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation for Hematological Diseases, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Yingjun ChangBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation for Hematological Diseases, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Xiaojun HuangBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation for Hematological Diseases, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Yueyun LaiBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation for Hematological Diseases, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although there is evolving consensus to re-evaluate cytogenetic features during follow-up in multiple myeloma (MM), longitudinal studies on cytogenetic evolution in Chinese MM patients are still lacking. Our aim was to highlight the importance of ongoing monitoring of cytogenetic characteristics and shed light on the implications of clonal evolution in Chinese MM patients. Patients and methods: The clinical data of 230 MM patients were retrospectively analyzed, including 100 patients were continuously monitored for cytogenetic abnormalities by fluorescence Results: 49 out of 100 patients acquired Conclusion: Re-evaluation of cytogenetic characteristics by serial FISH tests is important in MM patients.

Indexed as

clonal evolutioncytogeneticshigh-riskmultiple myelomasurvival

Identifiers

PMID40130247
PMCPMC11932419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.